The Types segment classifies Bioresorbable Drug-Eluting Stents by material composition and drug‑release architecture, chiefly into polymeric (PLLA‑based) and magnesium‑alloy platforms, each with distinct performance envelopes. Polymeric stents, which constitute approximately 55 % of the market, rely on a poly‑l‑lactic acid matrix that degrades via hydrolysis over 12–24 months; they enable controlled elution of antiproliferative agents such as everolimus, supporting endothelial healing while minimizing late‑stage restenosis. Magnesium‑alloy devices, representing the remaining 45 %, resorb through corrosion, offering a shorter scaffold lifespan of 6–12 months and higher radial strength during the acute phase. This material‑based taxonomy influences cost structures, with polymeric systems generally commanding higher unit prices due to complex coating processes, whereas magnesium devices benefit from lower manufacturing overhead but require stricter handling protocols. The market taxonomy thus reflects a trade‑off between degradation kinetics, mechanical integrity, and drug‑delivery efficiency, guiding clinicians’ selection criteria and shaping manufacturers’ product‑development pipelines. Future iterations are likely to converge on hybrid alloys that combine rapid resorption with sustained drug release.
